Navigation Links
Schering-Plough Announces Results of the Early ACS Trial
Date:3/30/2009

-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to potential of INTEGRILIN and further actions under the clinical trials. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Item 1A. "Risk Factors" in the 2008 10-K, filed February 27, 2009.


'/>"/>
SOURCE Schering-Plough
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
2. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
3. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
4. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
5. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
6. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
7. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
8. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
9. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... -- QT Vascular Ltd., together with its subsidiaries ("QT Vascular" ... design, assembly and distribution of advanced therapeutic solutions for ... into an agreement with a group of investors (the ... This funding will strengthen the Group,s working capital which ... Dr. Eitan Konstantino , Ph.D., ...
(Date:7/27/2015)... York , July 27, 2015 ... Research "Bionics Market - Global Industry Analysis, Size, Share, Growth, ... valued at USD 7.96 billion in 2014, growing at a ... USD 20.49 billion in 2021. The global bionics ... number of accidents, which is leading to paralysis or amputation ...
(Date:7/27/2015)... , July 27, 2015 Dynatronics Corporation (NASDAQ: DYNT ... Solaris therapeutic modality products. This approval allows the company to sell ... countries around the world. "Receiving the CE Mark represents ... stated Kelvyn H. Cullimore Jr. , president and CEO of ... network into China , Japan ...
Breaking Medicine Technology:QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 2QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 4Dynatronics Awarded CE Mark Approval for Its Solaris Products 2
... trauma or,noise-induced hearing loss. By any name, it,s the ... 28 million Americans,have impaired hearing; for as many as ... December 2007 issue of Harvard Men,s,Health Watch., Acoustic ... exposure,is the most common cause, but recreational noise -- ...
... Proven to Significantly Improve Overall Survival in ... Patients ... 19 ,Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq:,ONXX) today ... a supplemental New Drug Application for Nexavar(R) (sorafenib),tablets for the ...
Cached Medicine Technology:Your Hearing May be at Risk, Says Harvard Men's Health Watch 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 3Nexavar First FDA-Approved Drug Therapy for Liver Cancer 4Nexavar First FDA-Approved Drug Therapy for Liver Cancer 5Nexavar First FDA-Approved Drug Therapy for Liver Cancer 6
(Date:7/27/2015)... , ... July 27, 2015 , ... The Maricopa ... aging out of the foster care system to get into and complete college. ... was introduced at an event today with partners from across the valley. , ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... professional and in-depth research report. The report provides basic information such as ... etc. This report covers the global (US, Europe, Japan etc) industry analysis ...
(Date:7/27/2015)... ... 27, 2015 , ... Throughout its 20 year history, Doctors on Liens ... on a lien basis. As the personal injury and medical industries have changed, ... to orthopedists, to pain management physicians, to psychologists and more. And while many ...
(Date:7/27/2015)... , ... July 27, 2015 , ... Recently, 10 ... Nine other respected water brands also made the organization’s list. As its name clearly ... label options available. Here is a description of the top three brands, along with ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... medical and diagnostics applications is rapidly increasing and is driven by focused research ... they are increasingly being evaluated for use in bio implants. MWCNTs are used ...
Breaking Medicine News(10 mins):Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 3Health News:Doctors on Liens Adds Highly Respected Physical Therapy Office in Los Angeles 2Health News:Best Water Brand Awards Presented by 10 Best Water 2Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 2Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 3
... and Welfare (AIHW) it is found that Obstetrics department generates ... new report shows that one in five cases of negligence ... medical field was going through a period of crisis. In ... of doctors' negligence insurance for which the doctors were threatening ...
... to clinical trials, Union Minister for Health and Family Welfare ... as a guinea pig'//. ,'If you do clinical trials ... very guarded. We will not allow our population to suffer,' ... have laws and we are going to strengthen them,' the ...
... a new test to identify patients who develop bowel cancer ... fault is unveiled ,today//. ,An Edinburgh University team ... the New England Journal of Medicine. They explained that the ... then get the best treatment and will help identify relatives ...
... has said that the insurance industry is unfair in dealing ... insurance or are being asked to pay higher premiums even ... ,A survey conducted by the charity found that 90 percent ... say that it is not only cancer patients, but anyone ...
... consumption without a break is threatening to compete with ... manufactured by Wyeth Pharmaceuticals, is awaiting approval by health ... slip to the monthly period! Currently unavailable in neither ... period marked by extensive clinical trials. , ,This ...
... details about running a joint campaign fronted by the ... of family meals as a method of improving the ... departure for government public health campaigns in its tie-up ... report, which stated that such partnerships should be encouraged ...
Cached Medicine News:Health News:A New Test Developed to Identify Suspected Bowel Cancer Patients 2